Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gene editing
Biotech
Omega halts sole clinical-stage asset to focus on 3 programs
Omega is halting work on its clinical-stage candidate as part of a strategic refocus centered on three preclinical epigenomic controller programs.
James Waldron
Nov 15, 2024 5:33am
Spanish gene editor licenses DNA-cutting enzymes for up to $43M
Nov 4, 2024 1:46pm
Gene editor Tome laying off 131 workers
Aug 26, 2024 11:03am
8 months after $213M fundraise, gene editor Tome cuts costs
Aug 22, 2024 2:57pm
Bridge RNA from 'jumping genes' could overcome CRISPR limits
Jul 1, 2024 6:55am
Intellia doesn't need to re-dose NTLA-2001. But it can be done
Jun 25, 2024 3:31pm
